Hum. Reprod. Advance Access published online on July 16, 2008
Human Reproduction, doi:10.1093/humrep/den263
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome
1 Keogh Institute for Medical Research, Nedlands, WA, Australia 2 School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, Perth, WA, Australia 3 Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA 6009 Australia 4 International Diabetes Institute, Caulfield, Victoria, Australia
5 Correspondence address. Tel: +61-8-93462008; Fax: +61-8-93463003; E-mail: bstuckey{at}cyllene.uwa.edu.au
BACKGROUND: Polycystic ovary syndrome (PCOS) is associated with insulin resistance and features in common with the metabolic syndrome (MetS)—factors shown to predict cardiovascular risk and type 2 diabetes. We investigated the prevalence and characteristics of the MetS in PCOS by three definitions—World Health Organization (WHO), National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP-III) and International Diabetes Federation (IDF)—and compared that with the background population.
METHODS: Cross-sectional study of 168 women with PCOS and 883 age-matched controls from the Australian Diabetes, Obesity and Lifestyle (AusDiab) study.
RESULTS: Prevalence of the MetS in PCOS subjects was 33% by WHO, 37% by NCEP-ATP-III and 40% by IDF criteria, compared with 10% by NCEP-ATP-III and 13% by IDF in controls (P < 0.001). MetS by WHO criteria was not calculated in the AusDiab population. Age was an independent predictor of MetS in PCOS and controls. The prevalence of MetS was significantly higher among those with PCOS (P = 0.027) in obese women (BMI > 30 kg/m2), and higher but not significantly so in overweight (BMI 25–30 kg/m2) women (P = 0.052). Dehydroepiandrosterone sulphate was associated with a lower risk of the MetS—Odds ratio 0.86 (95% confidence interval, 0.77–0.97, P = 0.011).
CONCLUSIONS: An approximate 4-fold increase in the prevalence of the MetS in women with PCOS compared with the general population, consistent with the proposed major role of insulin and obesity in the syndrome, implies greater risk of cardiometabolic disease in women with PCOS. However, this estimate is likely to vary according to PCOS definition, ethnicity and different aetiological pathways to PCOS.
Key words: polycystic ovary syndrome/metabolic syndrome/insulin resistance/cardiovascular risk
Submitted on January 22, 2008; resubmitted on May 17, 2008; accepted on May 28, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R.-m. Ni, Y. Mo, X. Chen, J. Zhong, W. Liu, and D. Yang Low prevalence of the metabolic syndrome but high occurrence of various metabolic disorders in Chinese women with polycystic ovary syndrome Eur. J. Endocrinol., September 1, 2009; 161(3): 411 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Shi, M. K. Dyck, R. R. E. Uwiera, J. C. Russell, S. D. Proctor, and D. F. Vine A Unique Rodent Model of Cardiometabolic Risk Associated with the Metabolic Syndrome and Polycystic Ovary Syndrome Endocrinology, September 1, 2009; 150(9): 4425 - 4436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Moran and H. Teede Metabolic features of the reproductive phenotypes of polycystic ovary syndrome Hum. Reprod. Update, July 1, 2009; 15(4): 477 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Homburg Androgen circle of polycystic ovary syndrome Hum. Reprod., July 1, 2009; 24(7): 1548 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Wiltgen, I.G. Benedetto, L.S. Mastella, and P.M. Spritzer Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome Hum. Reprod., July 1, 2009; 24(7): 1726 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.J. Goverde, A.J.B. van Koert, M.J. Eijkemans, E.A.H. Knauff, H.E. Westerveld, B.C.J.M. Fauser, and F.J. Broekmans Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria Hum. Reprod., March 1, 2009; 24(3): 710 - 717. [Abstract] [Full Text] [PDF]
|
|